Screener
SELLAS Life Sciences Group, Inc. SLS Total Cost of Revenue
Discontinued — last reported Q4 '23
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by SELLAS Life Sciences Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: SELLAS Life Sciences Group, Inc.’s 10-K, filed March 28, 2024.
- Filed
- Mar 28, 2024
- Fiscal year
- FY2023
- Accession
- 0001390478-24-000004
| Line item | Year Ended December 31, 2023 | 2022 |
|---|---|---|
| Licensing revenue | — | $1,000 |
| Operating expenses: | ||
| Cost of licensing revenue | — | 100 |
| Research and development | 24,007 | 20,268 |
| General and administrative | 13,862 | 12,582 |
| Acquired in-process research and development | — | 10,000 |
| Total operating expenses | 37,869 | 42,950 |
| Loss from operations | (37,869) | (41,950) |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is SELLAS Life Sciences Group, Inc.'s total cost of revenue?
- SELLAS Life Sciences Group, Inc. (SLS) reported total cost of revenue of $0 in Q4 2023.
- What is the long-term trend for SELLAS Life Sciences Group, Inc.'s total cost of revenue?
- Over 2 years (2021 to 2023), SELLAS Life Sciences Group, Inc.'s total cost of revenue has grown at a -100.0% compound annual growth rate (CAGR), from $200K to $0.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about SELLAS Life Sciences Group, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude